Tag:

AstraZeneca

Latest Headlines

Latest Headlines

After many bitter setbacks, neurosciences R&D is making a comeback

Alzheimer's, depression, Parkinson's and the rest of the neuroscience targets of interest in biopharma have created a disaster zone for R&D teams in recent years. That's why AstraZeneca, GlaxoSmithKline and others have either pulled way back or completely out of the field. But in their wake, you can now detect a new generation of small biotechs stepping up with promising programs to revolutionize the field.

AstraZeneca's R&D boom gives EU a clean sweep of pipeline leaderboard

A 13% jump in the number of compounds in development at AstraZeneca has seen it leapfrog Pfizer ($PFE) to claim fourth place on Citeline's list of the biggest development pipelines. The switch means European Big Pharma companies occupy the top four spots, with GlaxoSmithKline, Novartis and Roche taking the podium positions.

FDA puts off Mylan's Nexium generic, giving Teva's version free rein

Good news for Teva when it comes to Mylan's generic version of AstraZeneca's Nexium: It won't be around for a little while.

AstraZeneca continues its respiratory land grab with $600M-plus Actavis deal

AstraZeneca CEO Pascal Soriot has said he wants to dominate in the respiratory field. Actavis CEO Brent Saunders has no such ambitions. Now, the two have struck a deal.

AstraZeneca embraces the biotech lifestyle in a make-or-break year

AstraZeneca's R&D blueprint for 2015 calls for hunkering down on its core pipeline assets and taking a cue from the startup world with the rest, CEO Pascal Soriot said, planning to partner up in hopes of maximizing value.

AstraZeneca stares down protesters' last-ditch effort to derail new HQ

A small army of protesters united by a diverse set of causes has mobilized in a last-ditch effort to throw up a roadblock to AstraZeneca's ambitious plans to build a sprawling new corporate headquarters and research center in Cambridge, U.K. But the angry backlash against its plans appears to have little chance of delaying the centerpiece project in the pharma giant's big comeback effort.

Moody's: Big Pharmas face growing patent-loss threats, but some pipelines are improving

For the past couple of years, the pharma industry has had something of a reprieve from patent-cliff nightmares. But according to Moody's Investors Service, some companies face new threats to their sweet dreams.

UPDATED: AstraZeneca partner Ardelyx plunges after citing safety issue for lead drug

Four months after getting a promising readout on its lead drug in a Phase IIb study for irritable bowel syndrome, AstraZeneca-partnered Ardelyx reported another study win today, but investors zeroed in on a disturbing safety issue and ripped up the company's shares soon after the release went out.

AstraZeneca bolts together a top transatlantic team for CRISPR R&D

In a broad-ranging slate of tech collaborations, AstraZeneca is allying itself with several top research institutions to hone its ability to apply CRISPR gene editing techniques to its drug development work. And the pharma giant used this alliance to pick some of the best brains in the business, without turning to any of the pioneers who have recently spawned a lineup of upstart biotechs.

AstraZeneca strikes deal with Box as IT revamp continues

Box has added a big-name client just days after pulling off a $175 million IPO. The deal sees AstraZeneca join Allergan and Eli Lilly on the list of major biopharma companies that use Box's cloud content sharing and collaboration tools.